Journal Watch · Leukemia · 2026

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

These results highlight the biological and prognostic relevance of molecular profile in TN-ET.

Carreño-Tarragona G, Gil-Manso R, Hernández-Boluda JC et al.Leukemia3 min readPharma relevance 65/100

DOI: 10.1038/s41375-026-03035-9PMID: 42443413Study type: cohort / observational clinical study

TL;DR

These results highlight the biological and prognostic relevance of molecular profile in TN-ET.

Key findings

  • Revised IPSET-thrombosis was useful for risk stratification (10-year probability of overall thrombosis: 30%, 15%, and 6% for high-, intermediate-, and very-low risk patients, respectively, p < 0.001).
  • ARTS score refined arterial thrombosis stratification (10 years probability: 25% and 6% for high- and low-risk, respectively, p < 0.001).
  • Progression to myelofibrosis was a rare event in this cohort (2.5%).
  • These results highlight the biological and prognostic relevance of molecular profile in TN-ET.

Numbers at a glance (from the abstract)

19.5%19.6%6.5%95%30%15%6%25%2.5%HR 12.608HR 3.008p < 0.001

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

53, p < 0.001) and had a higher frequency of prior thrombosis (19.6% vs. 6.5%, p = 0.013). Presence of pathogenic/likely pathogenic variants was associated with leukemic progression (HR 12.608; 95% CI: 2.616-60.775, p = 0.002) and lower overall survival (HR 3.008; 95% CI: 1.43-6.327, p = 0.004). ASXL1 (p = 0.004), CBL (p < 0.001), EZH2 (p < 0.001), and ZRSR2 (p < 0.001) mutations were associated with inferior leukemia-free survival. Age over 60 years, previous thrombosis, and cardiovascular risk factors were associated with higher thrombotic risk.

Full abstract (original)

Background: Triple-negative essential thrombocythemia (TN-ET) represents a diagnostic and therapeutic challenge. The aim of the present study was to identify prognostic factors useful for tailoring treatment. 241 TN-ET patients with myeloid panel sequencing and confirmatory bone marrow biopsy were selected. Pathogenic/likely pathogenic variants were identified in 19.5% of patients. Mutation carriers were older (median age 66 years vs.

What they did: 53, p < 0.001) and had a higher frequency of prior thrombosis (19.6% vs. 6.5%, p = 0.013). Presence of pathogenic/likely pathogenic variants was associated with leukemic progression (HR 12.608; 95% CI: 2.616-60.775, p = 0.002) and lower overall survival (HR 3.008; 95% CI: 1.43-6.327, p = 0.004). ASXL1 (p = 0.004), CBL (p < 0.001), EZH2 (p < 0.001), and ZRSR2 (p < 0.001) mutations were associated with inferior leukemia-free survival. Age over 60 years, previous thrombosis, and cardiovascular risk factors were associated with higher thrombotic risk.

Results & conclusions: Revised IPSET-thrombosis was useful for risk stratification (10-year probability of overall thrombosis: 30%, 15%, and 6% for high-, intermediate-, and very-low risk patients, respectively, p < 0.001). ARTS score refined arterial thrombosis stratification (10 years probability: 25% and 6% for high- and low-risk, respectively, p < 0.001). Progression to myelofibrosis was a rare event in this cohort (2.5%). These results highlight the biological and prognostic relevance of molecular profile in TN-ET.

Abstract © the authors / Leukemia (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41375-026-03035-9 · PubMed 42443413.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Leukemia for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Leukemia study find?

These results highlight the biological and prognostic relevance of molecular profile in TN-ET.

What type of study is this?

It is a cohort / observational clinical study, published in Leukemia in 2026. 53, p < 0.001) and had a higher frequency of prior thrombosis (19.6% vs.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41375-026-03035-9. PubMed ID: 42443413. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Carreño-Tarragona G, Gil-Manso R, Hernández-Boluda JC et al.. Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.. Leukemia (2026). DOI: 10.1038/s41375-026-03035-9.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/mutational-profile-and-cardiovascular-risk-factors-impact-prognosis-in-t-030359/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides